Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2021-12-10 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-12-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease agreement for office and laboratory space. It includes details about the lease terms and references the lease agreement as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a significant contractual event affecting the company, which fits the category of Capital/Financing Update (CAP) because it relates to a financial obligation and lease agreement. The document length is 4418 characters, which is typical for an 8-K filing of this nature. Therefore, the appropriate classification is CAP with high confidence.
2021-12-01 English
FORM 4 SUBMISSION
Director's Dealing
2021-11-17 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2021, by Xenon Pharmaceuticals Inc. It announces the company's financial results for the three and nine month periods ended September 30, 2021, via a press release attached as an exhibit. The text explicitly states that the information is furnished but not filed, and the press release is attached as Exhibit 99.1. The document does not contain the actual financial statements or detailed financial data but rather announces the results and provides a press release. The length is 3432 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such announcements of financial results with an attached press release but without substantive financial data should be classified as Earnings Release (ER).
2021-11-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.